Le Lézard
Classified in: Health, Business
Subject: ATY

Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV


NEW YORK, Sept. 10, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Verve Therapeutics, Inc. ("Verve Therapeutics" or the "Company") (NASDAQ: VERV) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Verve Therapeutics investors who were adversely affected by alleged securities fraud between August 9, 2022 and April 1, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/verve-therapeutics-inc-lawsuit-submission-form?prid=101198&wire=4

VERV investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that:  (1) defendants did not fully disclose the circumstances under which the Heart-1 Phase 1b clinical trial of VERVE-101, its investigational gene editing medicine, would be halted; (2) defendants overstated the potential benefits of its proprietary lipid nanoparticle delivery system; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT'S NEXT? If you suffered a loss in Verve Therapeutics during the relevant time frame, you have until October 28, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP


These press releases may also interest you

at 13:25
The "Protein Expression Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Protein Expression System, Protein Expression-related Offerings, Application Area, End-users, Type of Operation, Geography and Key Players" report...

at 13:21
The Bob Woodruff Foundation (BWF) has activated its  Natural Disaster Fund, established with support from Craig Newmark Philanthropies, to provide critical aid to veterans and military families in the Southeastern US who are affected by the...

at 13:11
26North Partners LP ("26North"), a next-generation alternatives firm founded by Josh Harris, announced today that it has acquired leading health club operator Onelife Fitness from Delos Capital ("Delos"). With locations across the Mid-Atlantic and...

at 13:00
October 5 is the International Day of No Prostitution (IDNP). On the occasion of IDNP 2024, the Women's Equality Coalition marks the 10th anniversary of the Protection of Communities and Exploited Persons Act, 2014, which recognizes prostitution as...

at 12:30
KalVista Pharmaceuticals, Inc. , today announced that it presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF) taking place...

at 12:30
CSL Seqirus has received a Biomedical Advanced Research and Development Authority (BARDA) award to complete the fill and finish process for additional pre-pandemic vaccines to further support the U.S. government's outbreak and preparedness...



News published on and distributed by: